Image

The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms

The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms

Non Recruiting
18-70 years
All
Phase 4

Powered by AI

Overview

The aim of this project is to investigate:

  • The status of the central serotonin (5-hydroxytryptamine, 5-HT) system in compulsive behaviour and how it is affected by sub-chronic escitalopram administration
  • The mechanisms underlying how sub-chronic administration of escitalopram affects the central 5-HT system
  • How changes in cognitive performance, including the balance between habitual and goal-directed mechanisms, are affected in compulsive behaviour by boosting 5-HT function
  • How functional brain changes in cognitive function measured with magnetic resonance imaging relate to altered 5-HT function following escitalopram administration.

Description

Previous studies have shown that 5-HT is strongly implicated in compulsive behaviours in experimental animals. Manipulation of 5-HT influences neuronal interactions underlying action selection. Reduced forebrain 5-HT causes perseveration and impairs goal-directed behaviour under reward but not punishment. Dysfunctional 5-HT neurotransmission has also been implicated in Obsessive-Compulsive Disorder (OCD) based on the selective efficacy of relatively high doses of selective serotonin reuptake inhibitors (SSRIs) in treating this disorder. Hitherto, it is unknown whether there is a primary defect in the serotonergic system or whether SSRIs ameliorate symptoms by modulating other brain neurotransmitter pathways. So far, only one study of central 5-HT release in OCD patients has been conducted and its methodology may be questioned.

A number of behavioural and cognitive features of OCD, including endophenotype markers that appear to characterise the disorder have been determined. These include a shift in cognitive control from a goal-directed strategy to a habitual (stimulus-response, S-R) strategy, cognitive rigidity in terms of both reversal learning and attentional set-shifting, impaired response inhibition and planning, and a tendency to over-respond to spurious negative feedback in a probabilistic learning paradigm. Neural substrates of these deficits are being investigated using brain imaging methodologies based on magnetic resonance and preliminary evidence suggests an over-active medial prefrontal cortex-caudate nucleus circuits and underactive lateral prefrontal cortex-putamen circuits. However, little evidence exists that relates to the hypothesis of an over-active habit system in this disorder or to the role of serotonin in all these cognitive and behavioural deficits observed in OCD and compulsivity in general.

Eligibility

Inclusion Criteria:

  • OCD patients, compulsive individuals without an OCD diagnosis, and healthy volunteers (male or female) between 18 and 70 years. Compulsive individuals without an OCD diagnosis are individuals without a history of psychiatric or other major medical conditions but scoring abnormally high on the Obsessive-Compulsive Inventory (OCI) questionnaire.

Exclusion Criteria:

  • Current or previous neurological disease, severe somatic disease, or consumption of medical drugs likely to influence the test results
  • Non- fluent in Danish or pronounced visual or auditory impairments
  • Current or past learning disability.
  • Pregnancy (females).
  • Lactation (females).
  • Participation in experiments with radioactivity (> 10 mSv) within the last year or significant occupational exposure to radioactivity.
  • Contraindications for MRI (pacemaker, metal implants, etc.).
  • Allergy to the ingredients in the administered drug.
  • Abnormal ECG (e.g. prolonged QT syndrome).
  • Dizzy when changing from supine to upright position (e.g. postural orthostatic tachycardia syndrome).
  • Mild hypotension (blood pressure below 100/70 mmHg) or hypertension (blood pressure above 140/90 mmHg).
  • Head injury or concussion resulting in loss of consciousness for more than 2 min.
  • Alcohol or drug abuse
  • Drug use other than tobacco and alcohol within the last 30 days.
  • Hash > 50 x lifetime.
  • Drugs > 10 x lifetime (for each substance).
  • Current medication with serotonergic acting compounds. Use of other psychoactive substances must be stable at least one month prior to inclusion and maintained throughout the study.
  • Severe physical impairments affecting eyesight or motor performance.
  • For the OCD group: other Axis I mental disorder as primary diagnosis according to ICD-10 criteria.
  • For healthy volunteers: any current or former primary psychiatric disorder (Axis I WHO ICD-10 diagnostic classification).

Study details
    Obsessive-Compulsive Disorder/High Compulsive Individuals
    Healthy Individuals

NCT04336228

Rigshospitalet, Denmark

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.